Table 2. Recurrence of venous thromboembolism and incidence of major bleeding in patients with deep venous thrombosis treated with new oral anticoagulants and comparison with standard treatment.

Comparison	Patients	Recurrence of deep venous thrombosis or venous embolism (OR, 95%CI)	Major bleeding	Quality of studies contributing to meta-analysis
Direct thrombin inhibitors (ximelagatran, dabigatran)	7,596 patients, mean age (min 54.7, max. 57.1)	≤ 3 months: OR 1.09 (95%CI 0.62-1.91);	≤ 3 months: (OR 0.54; 95%CI 0.28-1.03);	Authors’ judgment: “We deemed all included studies to be of high methodological quality and generally low risk of bias.”
		> 3 months: OR 1.09 (95%CI 0.76-1.58);	> 3 months: (OR 0.76; 95%CI 0.49-1.18);
		6 months: 1.09 (95%CI 0.80-1.49)	6 months: OR 0.68 (95%CI 0.47-0.98)
Direct factor Xa inhibitors (apixaban, rivaroxaban, edoxaban)	16,356 patients mean age (min. 53.1, max. 60)	≤ 3 months: OR 0.69 (95%CI 0.48-0.99);	≤ 3 months: OR 0.83 (95%CI 0.47-1.45);	Authors’ judgment: “We deemed all included studies to be of high methodological quality and generally low risk of bias.”
		> 3 months: OR 0.97 (95%CI 0.78-1.22);	> 3 months: OR 0.50 (95%CI 0.36-0.71);
		6 months: 0.89 (95%CI 0.73-1.07)	6 months: OR 0.57 (95%CI 0.43-0.76)

OR: odds ratio; CI: confidence interval.